Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02123992 · ClinicalTrials.gov registry record · Phase 4
Study of the Elevate Apical and Posterior Prolapse Repair System Compared to Native Tissue Repair for Pelvic Organ Prolapse
A Phase 4 study, sponsored by ASTORA Women's Health.
- Terminated
- Registry status
- Phase 4
- Development phase
- 99
- Enrollment target
NCT02123992: Clinical Trial Phase 4 study, sponsored by ASTORA Women's Health.
NCT02123992 is a Phase 4 study that was terminated before completion, run by ASTORA Women's Health. The registered enrollment target is 99 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02123992, a Phase 4 study, was terminated before completion, sponsored by ASTORA Women's Health.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 99 participants
- Enrollment target
Study Summary
The aim of this study is to further evaluate the safety and efficacy of the Elevate® Apical and Posterior Prolapse Repair System for repair of apical/posterior pelvic organ prolapse in a controlled, post-market cohort study.
Interventions
- DEVICE Elevate Apical and Posterior
- PROCEDURE Native Tissue Repair for pelvic organ prolapse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2014-04 |
| Est. Completion | 2019-04 |
| Phase | Phase 4 |
Why NCT02123992 stopped before completion
NCT02123992 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Elevate Apical and Posterior is the first listed.
NCT02123992 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02123992 about?
NCT02123992 is a clinical study titled "Study of the Elevate Apical and Posterior Prolapse Repair System Compared to Native Tissue Repair for Pelvic Organ Prolapse". The aim of this study is to further evaluate the safety and efficacy of the Elevate® Apical and Posterior Prolapse Repair System for repair of apical/posterior pelvic organ prolapse in a controlled, post-market cohort study.
What is the current status of trial NCT02123992?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 99 participants. The study started on 2014-04. Estimated completion is 2019-04.
What interventions are being tested in trial NCT02123992?
The interventions under investigation include: Elevate Apical and Posterior (DEVICE), Native Tissue Repair for pelvic organ prolapse (PROCEDURE).
Who is sponsoring clinical trial NCT02123992?
This trial is sponsored by ASTORA Women's Health, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02123992's enrollment target sits among peer trials
99 853rd of 2000 higher than 1,147 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia